Progress of minimal residual disease studies in childhood acute leukemia

Current Hematologic Malignancy Reports

Volumn 5, Issue 3, 2010, Pages 169-176

  Campana, Dario ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Acute lymphoblastic leukemia; Acute myeloid leukemia; Flow cytometry; Polymerase chain reaction

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; CANCER DIAGNOSIS; CANCER RELAPSE; CHILD; CHILDHOOD LEUKEMIA; FLOW CYTOMETRY; GENE MUTATION; HUMAN; IMMUNOPHENOTYPING; MINIMAL RESIDUAL DISEASE; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PROGNOSIS; REVIEW; SCHOOL CHILD; TREATMENT OUTCOME;

CHILD; CLINICAL TRIALS AS TOPIC; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA, MYELOID, ACUTE; NEOPLASM, RESIDUAL; POLYMERASE CHAIN REACTION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 77955985275     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-010-0056-8     Document Type: Review

References (58)

1. Jacquillat C, Weil M, Gemon MF, et al.: Combination therapy in 130 patients with acute lymphoblastic leukemia (protocol 06 LA 66-Paris). Cancer Res 1973, 33:3278-3284.
2. Wheatley K, Burnett AK, Goldstone AH, et al.: A simple, robust, validated and highly predictive index for the determination of riskdirected therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties. Br J Haematol 1999, 107:69-79.
3. Sandlund JT, Harrison PL, Rivera G, et al.: Persistence of lymphoblasts in bone marrow on day 15 and days 22 to 25 of remission induction predicts a dismal treatment outcome in children with acute lymphoblastic leukemia. Blood 2002, 100:43-47.
4. Campana D: Status of minimal residual disease testing in childhood haematological malignancies. Br J Haematol 2008, 143:481-489.
5. Szczepanski T, Orfao A, van der Velden VH, et al.: Minimal residual disease in leukaemia patients. Lancet Oncol 2001, 2:409-417.
6. Coustan-Smith E, Ribeiro RC, Rubnitz JE, et al.: Clinical significance of residual disease during treatment in childhood acute myeloid leukemia. Br J Haematol 2003, 123:243-252.
7. Rubnitz JE, Inaba H, Dahl GV, et al.: Minimal residual diseasedirected therapy for childhood acute myeloid leukemia: results of the AML02 multicentre trial. Lancet Oncol 2010, in press. This is the first childhood AML study using MRD for risk assignment.
8. Boeckx N, Willemse MJ, Szczepanski T, et al.: Fusion gene transcripts and Ig/TCR gene rearrangements are complementary but infrequent targets for PCR-based detection of minimal residual disease in acute myeloid leukemia. Leukemia 2002, 16:368-375.
9. Kottaridis PD, Gale RE, Langabeer SE, et al.: Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors. Blood 2002, 100:2393-2398.
10. Farr C, Gill R, Katz F, et al.: Analysis of ras gene mutations in childhood myeloid leukaemia. Br J Haematol 1991, 77:323-327.
11. Brown P, McIntyre E, Rau R, et al.: The incidence and clinical significance of nucleophosmin mutations in childhood AML. Blood 2007, 110:979-985.
12. Cilloni D, Renneville A, Hermitte F, et al.: Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: A European LeukemiaNet study. J Clin Oncol 2009, 27:5195-5201.
13. Jacobsohn DA, Tse WT, Chaleff S, et al.: High WT1 gene expression before haematopoietic stem cell transplant in children with acute myeloid leukaemia predicts poor event-free survival. Br J Haematol 2009, 146:669-674.
14. Willasch AM, Gruhn B, Coliva T, et al.: Standardization of WT1 mRNA quantitation for minimal residual disease monitoring in childhood AML and implications of WT1 gene mutations: A European multicenter study. Leukemia 2009, 23:1472-1479.
15. Sievers EL, Lange BJ, Alonzo TA, et al.: Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 acute myeloid leukemia patients. Blood 2003, 101:3398-3406.
16. Langebrake C, Creutzig U, Dworzak M, et al.: Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM Study Group. J Clin Oncol 2006, 24:3686-3692.
17. Rosenberg AR, Leisenring W, Sanders JE, et al.: Sub-morphologic evidence of disease prior to stem cell transplantation correlates with inferior post transplant outcome in childhood acute myeloid leukemia [abstract]. Blood (ASH Annual Meeting Abstracts) 2009, 114:328.
18. Gabert J, Beillard E, van der Velden V, et al.: Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia-a Europe Against Cancer program. Leukemia 2003, 17:2318-2357.
19. Viehmann S, Teigler-Schlegel A, Bruch J, et al.: Monitoring of minimal residual disease (MRD) by real-time quantitative reverse transcription PCR (RQ-RT-PCR) in childhood acute myeloid leukemia with AML1/ETO rearrangement. Leukemia 2003, 17:1130-1136.
20. Perea G, Lasa A, Aventin A, et al.: Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)]. Leukemia 2006, 20:87-94.
21. Coustan-Smith E, Sancho J, Behm FG, et al.: Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia. Blood 2002, 100:52-58.
22. van der Velden V, Cazzaniga G, Schrauder A, et al.: Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia 2007, 21:604-611.
23. Flohr T, Schrauder A, Cazzaniga G, et al.: Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia 2008, 22:771-782.
24. Neale GA, Coustan-Smith E, Stow P, et al.: Comparative analysis of flow cytometry and polymerase chain reaction for the detection of minimal residual disease in childhood acute lymphoblastic leukemia. Leukemia 2004, 18:934-938.
25. Kerst G, Kreyenberg H, Roth C, et al.: Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR. Br J Haematol 2005, 128:774-782.
26. Ryan J, Quinn F, Meunier A, et al.: Minimal residual disease detection in childhood acute lymphoblastic leukaemia patients atmultiple time-points reveals high levels of concordance between molecular and immunophenotypic approaches. Br J Haematol 2009, 144:107-115.
27. Coustan-Smith E, Behm FG, Sanchez J, et al.: Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet 1998,351:550-554.
28. Coustan-Smith E, Sancho J, Hancock ML, et al.: Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood 2000, 96:2691-2696.
29. Dworzak MN, Froschl G, Printz D, et al.: Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. Blood 2002, 99:1952-1958.
30. Borowitz MJ, Devidas M, Hunger SP, et al.: Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors. a Children's Oncology Group study. Blood 2008, 111:5477-5485.
31. Basso G, Veltroni M, Valsecchi MG, et al.: Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow. J Clin Oncol 2009, 27:5168-5174. This large study comfirms the prognostic significance of detecting MRD during remission induction therapy by flow cytometry.
32. Brisco MJ, Condon J, Hughes E, et al.: Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction. Lancet 1994, 343:196-200.
33. Cave H, van der Werff ten Bosch J, Suciu S, et al.: Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer-Childhood Leukemia Cooperative Group. N Engl J Med 1998, 339:591-598.
34. van Dongen JJ, Seriu T, Panzer-Grumayer ER, et al.: Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 1998, 352:1731-1738.
35. Conter V, Bartram CR, Valsecchi MG, et al.: Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood 2010 Feb 12 (Epub ahead of print). This large study confirms the clinical importance of MRD detected by PCR amplification of IG and TCR genes in childhood ALL.
36. Zhou J, Goldwasser MA, Li A, et al.: Quantitative analysis of minimal residual disease predicts relapse in children with Blineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01. Blood 2007, 110:1607-1611.
37. Stow P, Key L, Cjen X, et al.: Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia. Blood 2010 March 19 (Epub ahead of print).
38. Biondi A, Valsecchi MG, Seriu T, et al.: Molecular detection of minimal residual disease is a strong predictive factor of relapse in childhood B-lineage acute lymphoblastic leukemia with medium risk features. A case control study of the International BFM study group. Leukemia 2000, 14:1939-1943.
39. Attarbaschi A,Mann G, Panzer-Grumayer R, et al.:Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials. J Clin Oncol 2008, 26:3046-3050.
40. van der Velden V, Corral L, Valsecchi MG, et al.: Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol. Leukemia 2009, 23:1073-1079
41. Eckert C, Biondi A, Seeger K, et al.: Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia. Lancet 2001, 358:1239-1241.
42. Coustan-Smith E, Gajjar A, Hijiha N, et al.: Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse. Leukemia 2004, 18:499-504.
43. Paganin M, Zecca M, Fabbri G, et al.: Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia. Leukemia 2008, 22:2193-2200.
44. Raetz EA, Borowitz MJ, Devidas M, et al.: Reinduction platform for children with first marrow relapse of acute lymphoblastic leukemia: A Children's Oncology Group study [corrected]. J Clin Oncol 2008, 26(24):3971-3978.
45. Hagedorn N, Acquaviva C, Fronkova E, et al.: Submicroscopic bone marrow involvement in isolated extramedullary relapses in childhood acute lymphoblastic leukemia: A more precise definition of "isolated" and its possible clinical implications, a collaborative study of the Resistant Disease Committee of the International BFM Study Group. Blood 2007, 110:4022-4029.
46. Bader P, Kreyenberg H, Henze GH, et al.: Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group. J Clin Oncol 2009, 27:377-384.
47. Pui CH, Campana D, Pei D, et al.: Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med 2009, 360:2730-2741. This was the first published study to use MRD for risk stratification in newly diagnosed childhood ALL.
48. Coustan-Smith E, Sancho J, Hancock ML, et al.: Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia. Blood 2002, 100:2399-2402.
49. van der Velden V, Jacobs DC, Wijkhuijs AJ, et al.: Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL. Leukemia 2002, 16:1432-1436.
50. Panzer-Grumayer ER, Schneider M, Panzer S, et al.: Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia. Blood 2000, 95:790-794.
51. Coustan-Smith E, Ribeiro RC, Stow P, et al.: A simplified flow cytometric assay identifies children with acute lymphoblastic leukemia who have a superior clinical outcome. Blood 2006, 108:97-102.
52. Campana D: Molecular determinants of treatment response in acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2008, 2008:366-373.
53. Mullighan CG, Su X, Zhang J, et al.: Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med 2009, 360:470-480.
54. Coustan-Smith E, Mullighan CG, Onciu M, et al.: Early T-cell precursor leukaemia: A subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol 2009,10:147-156.
55. Cario G, Stanulla M, Fine BM, et al.: Distinct gene expression profiles determine molecular treatment response in childhood acute lymphoblastic leukemia. Blood 2005,105:821-826.
56. Flotho C, Coustan-Smith E, Pei D, et al.: Genes contributing to minimal residual disease in childhood acute lymphoblastic leukemia: prognostic significance of CASP8AP2. Blood 2006, 108:1050-1057.
57. Flotho C, Coustan-Smith E, Pei D, et al.: A set of genes that regulate cell proliferation predicts treatment outcome in childhood acute lymphoblastic leukemia. Blood 2007, 110:1271-1277.
58. Yang JJ, Cheng C, Yang W, et al.: Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. JAMA 2009, 301:393-403.